扎尔鲁卡斯特
医学
咳嗽反射
白三烯受体
哮喘
白三烯
麻醉
白三烯D4
安慰剂
耐火材料(行星科学)
白三烯E4
交叉研究
内科学
胃肠病学
反射
病理
天体生物学
物理
替代医学
作者
Peter V. Dicpinigaitis,J. Dobkin,Joseph Reichel
标识
DOI:10.1081/jas-120002285
摘要
Cough-variant asthma (CVA) occurs in a subgroup of asthmatics whose sole or predominant respiratory symptom is cough. Although bronchodilators are often sufficient to treat CVA, refractory cough may require therapy with inhaled or systemic corticosteroids. In a randomized, double-blind, placebo-controlled, crossover study, we examined the effect of a 14-day course of the leukotriene receptor antagonist zafirlukast on subjective cough score and cough-reflex sensitivity to inhaled capsaicin in eight subjects with CVA refractory to inhaled beta agonists, and in five subjects refractory to inhaled corticosteroids. Seven of eight subjects experienced significant subjective and objective improvement in cough after treatment with zafirlukast. Mean (± SEM) cough score improved from 7.75 ± 0.56 to 3.25 ± 0.84 (p = 0.0006). Cough sensitivity to capsaicin was suppressed by zafirlukast in all subjects. Patients with CVA may represent a distinct subgroup of asthmatics whose afferent cough receptors within the respiratory epithelium are hypersensitive relative to those of patients with the typical form of asthma. Zafirlukast appears to be particularly effective in treating CVA by inhibiting the sensitivity of these receptors. Leukotriene receptor antagonists may offer an alternative to corticosteroids for the treatment of CVA refractory to inhaled bronchodilators.
科研通智能强力驱动
Strongly Powered by AbleSci AI